Compare Chevron Corp (CVX) vs Pfizer Inc (PFE) Price & Performance

Chevron (CVX) trades at $196.66, up 5.41% today, reflecting strong momentum amid high oil prices. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $214.25. Revenue declined to $184.43B in 2025, but net income margin held at 9.87%, with robust cash flow from operations of $33.94B. Recent news highlights strategic investments in Argentina and Greece, leveraging geopolitical tensions to boost production prospects.

Outlook is positive with oil price tailwinds and operational efficiency, but risks include volatile energy markets and debt increases. The stock offers a solid dividend yield and growth potential, supported by analyst bullishness, though investors should monitor execution on new projects and macroeconomic shifts affecting energy demand.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.